OlympiA: adjuvant olaparib in gBRCAm, HER2-negative, high-risk, early breast cancer скачать в хорошем качестве

OlympiA: adjuvant olaparib in gBRCAm, HER2-negative, high-risk, early breast cancer

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, speaks on the findings of OlympiA (NCT02032823), a randomized, double-blind, Phase III trial evaluating adjuvant olaparib after neoadjuvant chemotherapy in patients with germline BRCA1/2 mutations (gBRCAm) and high-risk HER2-negative early breast cancer. Adjuvant olaparib resulted in a significantly improved invasive disease-free survival and distant disease free-survival with acceptable toxicity. Dr Hamilton concludes by addressing the implications of this study, including increased access to coverage for BRCA testing. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.